CAR27 natural killer cells

CAR27 natural killer cells are an investigational **allogeneic cord blood-derived CAR NK-cell therapy** engineered to target **CD70** on tumor cells through the extracellular domain of **CD27**, the natural receptor for CD70. In the cited multiple myeloma program, the construct used clinically and in the accompanying preclinical work is commonly described as **CAR27/IL-15**, which adds IL-15 to improve NK-cell persistence and expansion; however, the exact queried term here is CAR27 natural killer cells rather than the more specific CAR27/IL-15 product. The therapy is being developed at **MD Anderson Cancer Center** with related technology licensed with **Takeda**, and is intended as an off-the-shelf cellular immunotherapy for **CD70-positive malignancies**, including **multiple myeloma**, particularly in patients with relapsed or high-risk disease and those progressing after BCMA-directed therapy. Mechanistically, these engineered NK cells recognize CD70-expressing cancer cells, trigger CAR-mediated cytotoxicity, and retain intrinsic NK-cell antitumor activity.

Other names

CAR27 natural killer cellsCAR-27 natural killer cellsCAR 27 natural killer cellsCD70-targeting CAR NK cellsCD-70-targeting CAR NK cellsCD 70-targeting CAR NK cellsCAR27 NK cellsCAR-27 NK cellsCAR 27 NK cellsCD27-based CAR natural killer cellsCD-27-based CAR natural killer cellsCD 27-based CAR natural killer cellsCD27-extracellular domain CAR natural killer cellsCD-27-extracellular domain CAR natural killer cellsCD 27-extracellular domain CAR natural killer cells